Gyre Therapeutics (GYRE) Asset Utilization Ratio (2011 - 2026)

Gyre Therapeutics (GYRE) has reported Asset Utilization Ratio for 15 consecutive years, with 0.71 the latest figure, recorded in Q1 2026.

• In Q1 2026, Asset Utilization Ratio fell 9.55% year-over-year to 0.71; the TTM figure through Mar 2026 stood at 0.71 (down 9.55% YoY), while the FY2025 annual figure was 0.8, down 8.51% from the prior year.
• Asset Utilization Ratio held at 0.71 in Q1 2026 per GYRE's latest filing, from 0.72 in the prior quarter.
• Across five years, Asset Utilization Ratio topped out at 16.8 in Q3 2023 and bottomed at 0.06 in Q3 2022.
• Historically, Asset Utilization Ratio has averaged 2.37 across 5 years, with a median of 0.84 in 2024.
• Annual changes were most pronounced in 2023 — Asset Utilization Ratio soared 29964.01% — and 2024, when it plunged 94.92%.
• Gyre Therapeutics' Asset Utilization Ratio stood at 1.77 in 2022, then gained by 1.5% to 1.79 in 2023, then tumbled by 52.95% to 0.84 in 2024, then slipped by 15.11% to 0.72 in 2025, then declined by 0.41% to 0.71 in 2026.
• Business Quant data shows GYRE's Asset Utilization Ratio at 0.71 in Q1 2026, 0.72 in Q4 2025, and 0.69 in Q3 2025.